Inclusion Criteria:  Age between 18 to 70 years old from all sex; Diagnosed with type 2 diabetes and HbA1c between 7% to 10%; BMI from 24 to 35kg/m² or waistline longger than 90cm（male）/85cm（female）; Volunteer to participate in the study with informed consent;  Exclusion Criteria:  Type 1 diabetes or other specific types of diabetes; Taking drugs of GLP-1 receptor agonist、TZDs and SGLT2 inhibitor within 3 months of screening; Taking insulin or insulin analogues more than 7 days within 3 months of screening; Pregnancy, breastfeeding or planned pregnancy; History of acute or chronic pancreatitis; Taking glucocorticoids(oral or intravenous) continuously more than 7 days within 6 months of screening; Alanine aminotransferase or aspartate transaminase more than 3 times of the normal upper limit, total bilirubin more than 2 times of the normal upper limit; renal impairment (estimated glomerular filtration rate<60mL/min per 1.73 m²); History of gastrointestinal disease; History of malignant tumor within 5 years of screening; History of organ transplantation or AIDS; History of glaucoma; History of hyperthyroidism or hypothyroidism; History of medullary thyroid carcinoma or multiple endocrine neoplasia II; History of abnormal of Calcitonin or thyroid tumor; History of alcohol abuse; Recruited by other clinical trials within 3 months of screening; Taking drugs of weight loss within 3 months of screening; History of bariatric surgery; History of mental disorders; History of rheumatic diseases or autoimmune diseases; Allergic to beinaglutide or dulaglutide; Participants who estimated would not be suitable for the study by the investigators.